Diabetes drug developer Arecor has appointed Susan Lowther as its new chief financial officer.
Lowther has “significant experience” in the life sciences industry, Arecor said, having previously been the finance boss of AIM-listed IXICO PLC (LON:IXI) until December last year.
She has also been the chief bean counter for French cancer diagnostics specialist Novacyt, RiboTargets and BioWisdom, a data analysis firm which was acquired by Instem PLC (LON:INS) back in 2011.
WATCH: Accor strengthens team with appointment of experienced CFO
Lowther started her career at British Gas before moving on to work for US biotech giant Monsanto.
“I am delighted that Susan is joining the Arecor team,” said chief executive Sarah Howell.
“She brings a depth of financial and business expertise that will help us to deliver our ambitious growth plans.
“Following the completion of our successful capital raise last year we are well positioned to leverage our proprietary formulation platform in the development of our clinical products and in technology partnerships with pharmaceutical or biotechnology companies.”
Lowther added: “This is an exciting time to join Arecor and become part of an innovative and ambitious team.”